Evotec's Horizon Plan Faces Its Reckoning as Pipeline Deals Inch Forward

Evotec shares have fallen 48% this year after a July guidance cut, with dilution and a wider EBITDA loss risk testing its Horizon restructuring.

Evotec has spent the better part of the year trying to convince investors that its worst stretch is behind it. The Hamburg-based drug discovery specialist is now in the thick of a transition that pits a sweeping cost-cutting drive against a market that has grown weary of promises. Whether the restructuring delivers fast enough has become the single question driving sentiment toward the stock.

A Guidance Cut That Still Stings

The turning point came in July, when management slashed its outlook for fiscal 2026 in no uncertain terms. Revenue is now projected at EUR 570 million to EUR 610 million, while adjusted EBITDA is expected to land between minus EUR 70 million and minus EUR 105 million. Delayed milestone payments and partnership agreements that slipped past their expected signing dates forced the revision.

That downgrade left a mark. At a recent price of EUR 2.86 — after closing at EUR 2.85 in a prior session — the shares have lost 48% since the start of the year, leaving the company with a market capitalization of EUR 496.48 million. The stock touched a fresh 52-week low of EUR 2.76 along the way, a reminder of how fragile confidence has become.

Dilution Adds a Second Layer of Pressure

Compounding the earnings setback, Evotec's capital structure shifted with the issuance of new subscription shares. Voting rights climbed to 177,909,968 as a result — a development that spells meaningful dilution for existing holders. Future profits, whenever they arrive, will now be spread across a larger share count. For institutional investors weighing the risk-reward, that arithmetic matters.

Science Keeps Moving, Even as the Numbers Lag

Against that grim financial backdrop, the company's research engines have not gone quiet. On September 2, Evotec struck a research collaboration with Plectonic Biotech aimed at developing T-cell-activating approaches for solid tumors. The partnership pairs Evotec's BiTCo platform with Plectonic's LOGIBODY technology, opening a new biological avenue in oncology.

Just – Evotec Biologics, meanwhile, pushed the antibody program JST-018 into a Phase I clinical trial. The candidate, directed against orthopoxviruses, sits within the U.S. Department of War's Accelerated Antibodies Program and carries a contract value of up to USD 123.9 million. The unit is running at high capacity utilization, a detail that underscores the underlying demand for its services.

The First-Half Scorecard

Interim results for the first half of 2026 frame the scale of the challenge. Group revenue came in at EUR 300.1 million, with adjusted EBITDA at minus EUR 42.7 million. Strip out partnership contributions, and D&PD revenue actually grew 28% year over year — evidence that the core business retains momentum even as the bottom line sags.

What the CFO Is Telling Investors

Chief Financial Officer Claire Hinshelwood used an investor conference to argue that business indicators are trending in the right direction, pointing to progress under the Horizon savings program. The initiative is designed to reshape the cost base and gradually restore profitability. But the market has heard the message before, and credibility will now be judged against hard numbers rather than reassurances.

The Thresholds That Matter

For traders positioning around the stock, the lines are fairly clear. As long as the recent low holds, the possibility of a bottoming pattern stays alive — provided upcoming quarterly reports show measurable relief from Horizon. Should the operating trend deteriorate instead and the projected EBITDA loss widen beyond EUR 105 million, the current valuation could give way to another leg of selling as faith in the turnaround fades.

The next set of business figures now serves as the key catalyst. Management will have to demonstrate that the deal pipeline and cost reductions are genuinely sufficient to engineer a reversal. Only verifiable progress on margins can set the stage for a sustained recovery — and until that materializes, the stock is likely to remain a waiting game.